Kuros Biosciences AG - Asset Resilience Ratio

Latest as of June 2025: 16.77%

Kuros Biosciences AG (KURN) has an Asset Resilience Ratio of 16.77% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Kuros Biosciences AG for a breakdown of total debt and financial obligations.

Liquid Assets

CHF18.44 Million
≈ $23.32 Million USD Cash + Short-term Investments

Total Assets

CHF109.97 Million
≈ $139.03 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2005–2023)

This chart shows how Kuros Biosciences AG's Asset Resilience Ratio has changed over time. See KURN net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Kuros Biosciences AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Kuros Biosciences AG market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CHF18.44 Million 16.77%
Short-term Investments CHF0.00 0%
Total Liquid Assets CHF18.44 Million 16.77%

Asset Resilience Insights

  • Good Liquidity Position: Kuros Biosciences AG maintains a healthy 16.77% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Kuros Biosciences AG Industry Peers by Asset Resilience Ratio

Compare Kuros Biosciences AG's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Demant A/S
CO:DEMANT
Medical Devices -2.59%
Sino Medical Sciences Technology In
SHG:688108
Medical Devices 0.66%
Polynovo Ltd
AU:PNV
Medical Devices 5.46%
Beijing Succeeder Technology Inc
SHG:688338
Medical Devices 28.66%
Tellgen Corp
SHE:300642
Medical Devices 8.60%
Respiri Ltd
AU:RSH
Medical Devices 0.46%
Diagnostic Medical Systems SA
PA:ALDMS
Medical Devices 1.39%
Duearity AB
ST:DEAR
Medical Devices 145.62%

Annual Asset Resilience Ratio for Kuros Biosciences AG (2005–2023)

The table below shows the annual Asset Resilience Ratio data for Kuros Biosciences AG.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 0.48% CHF342.00K
≈ $432.38K
CHF71.46 Million
≈ $90.35 Million
-1.52pp
2015-12-31 1.99% CHF65.00K
≈ $82.18K
CHF3.26 Million
≈ $4.12 Million
-10.99pp
2011-12-31 12.98% CHF4.00 Million
≈ $5.06 Million
CHF30.81 Million
≈ $38.96 Million
-1.81pp
2010-12-31 14.80% CHF8.00 Million
≈ $10.11 Million
CHF54.07 Million
≈ $68.36 Million
-39.06pp
2009-12-31 53.86% CHF37.00 Million
≈ $46.78 Million
CHF68.70 Million
≈ $86.86 Million
+16.84pp
2008-12-31 37.02% CHF41.00 Million
≈ $51.84 Million
CHF110.75 Million
≈ $140.02 Million
-16.40pp
2007-12-31 53.42% CHF66.00 Million
≈ $83.44 Million
CHF123.56 Million
≈ $156.21 Million
+22.06pp
2006-12-31 31.35% CHF18.00 Million
≈ $22.76 Million
CHF57.41 Million
≈ $72.58 Million
+30.89pp
2005-12-31 0.46% CHF379.00K
≈ $479.16K
CHF82.39 Million
≈ $104.17 Million
--
pp = percentage points

About Kuros Biosciences AG

SW:KURN Switzerland Medical Devices
Market Cap
$1.00 Billion
CHF794.48 Million CHF
Market Cap Rank
#9167 Global
#119 in Switzerland
Share Price
CHF20.28
Change (1 day)
-3.43%
52-Week Range
CHF20.28 - CHF33.36
All Time High
CHF36.96
About

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technol… Read more